Business Wire

TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the ...
Business Wire

TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that ...
BioWorld

Trexbio strengthens Lilly connection in $1.1B deal; Kronos, Selecta, 3T join dealmaking party

Trex Bio Inc., which kicked off 2022 with a big pharma partnership, is back at it again, starting the new year with a potential $1.1 billion agreement with original backer Eli Lilly and Co. targeting ...
Morningstar

TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics

Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other ...